Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $195.00 Price Target at TD Cowen

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective decreased by analysts at TD Cowen from $200.00 to $195.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. TD Cowen’s target price indicates a potential upside of 62.80% from the company’s previous close.

A number of other research firms also recently commented on JAZZ. Robert W. Baird cut their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st. Wells Fargo & Company lowered their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. Needham & Company LLC restated a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Finally, Morgan Stanley lowered their target price on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research note on Friday, July 12th. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.00.

Jazz Pharmaceuticals Trading Up 7.4 %

JAZZ stock traded up $8.23 during trading on Thursday, hitting $119.78. The company had a trading volume of 1,095,415 shares, compared to its average volume of 670,851. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The firm has a market capitalization of $7.40 billion, a P/E ratio of 20.58, a PEG ratio of 1.37 and a beta of 0.57. The company has a 50 day simple moving average of $110.42 and a 200-day simple moving average of $109.61. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $134.26.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported $5.86 EPS for the quarter, beating analysts’ consensus estimates of $4.54 by $1.32. The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.04 billion. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. As a group, research analysts forecast that Jazz Pharmaceuticals will post 16.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now directly owns 428,976 shares in the company, valued at approximately $47,547,699.84. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the transaction, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at $47,547,699.84. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now owns 14,531 shares of the company’s stock, valued at $1,573,707.30. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several hedge funds have recently made changes to their positions in JAZZ. Versant Capital Management Inc grew its holdings in shares of Jazz Pharmaceuticals by 13,450.0% during the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in shares of Jazz Pharmaceuticals during the second quarter worth about $29,000. EverSource Wealth Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 97 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP purchased a new position in shares of Jazz Pharmaceuticals during the second quarter worth about $33,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.